Partial
Partially Aligned
Patient Risk:
Low
Summary
Category Scores
Accurate Statements
Yupelri (revefenacin) is an inhaled, once-daily long-acting muscarinic antagonist (LAMA).
Partially supported by provided text only: Section 14 states YUPELRI 175 mcg is evaluated as 175 mcg once daily. No explicit label excerpt provided that confirms 'LAMA' or 'long-acting' wording.
Yupelri (revefenacin) has been developed for chronic obstructive pulmonary disease (COPD).
Supported indirectly by Section 1 indication (COPD maintenance treatment) and Section 14 clinical studies in COPD. Exact wording 'developed for' is not verbatim but consistent with the provided label excerpts.
The provided information does not include any approval or indication for asthma for Yupelri (revefenacin).
Consistent with the provided excerpt: Section 1 includes COPD maintenance treatment; no asthma indication is shown in the supplied text.
The provided information does not include asthma trial results for revefenacin.
Supported only by absence in the supplied excerpt: Section 14 described trials in COPD, and no asthma trial results are included in the provided text.
The provided information does not include regulatory outcomes for revefenacin in asthma.
Supported only by absence in the supplied excerpt; no asthma regulatory outcomes are provided in the supplied text.
Yupelri (revefenacin) is conceptually similar to other inhaled antimuscarinic bronchodilators used in obstructive airway diseases.
No supporting or contradicting label excerpt provided for this conceptual comparison.
In asthma care, LAMAs are sometimes used as add-on controller therapy depending on guideline context and local approvals.
No supporting or contradicting label excerpt provided regarding asthma or treatment guidelines.
The provided information does not include evidence or guideline support for asthma use of revefenacin.
Supported only by absence in the supplied excerpt; no asthma evidence/guideline support is included in the provided text.
maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
Section 1 INDICATIONS AND USAGE: 'YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).'
Unsupported Statements
Yupelri (revefenacin) is an inhaled, once-daily long-acting muscarinic antagonist (LAMA).
The provided excerpts only show 'once daily' dosing evaluation in Section 14 and COPD indication in Section 1. The excerpts do not explicitly state 'inhaled,' 'muscarinic antagonist,' 'LAMA,' or 'long-acting.'
Yupelri (revefenacin) is conceptually similar to other inhaled antimuscarinic bronchodilators used in obstructive airway diseases.
No label text in the provided excerpts supports or describes comparison to other antimuscarinics.
In asthma care, LAMAs are sometimes used as add-on controller therapy depending on guideline context and local approvals.
No label text in the provided excerpts supports statements about asthma treatment patterns or guidelines.
Contradictions
Important Omissions
If evaluating prescribing accuracy comprehensively, the label would typically include sections for contraindications, boxed warnings, warnings/precautions, drug interactions, and specific populations; none of these sections were provided in the prompt excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No dosing, safety, contraindication, or warning claims were made in a way that could be directly contradicted by the provided label excerpt. However, mechanistic/classification and asthma-related context statements were not supported by the supplied label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements (LAMA/long-acting classification and asthma-treatment context) are not supported by the provided FDA label excerpts, even though the COPD indication itself is supported.
Suggested Improvement
Limit claims to the provided label-supported text (e.g., COPD maintenance indication and 'once daily' dosing as shown in the clinical study excerpt) and avoid unsupported mechanistic/classification or asthma guideline/treatment assertions unless those sections are included in the label excerpt.